로타바이러스 백신 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of rotavirus vaccines Market

The global rotavirus vaccines market was valued at USD 5.22 billion in 2025 and is projected to grow to USD 5.57 billion in 2026, reaching USD 12.86 billion by 2034, exhibiting a strong CAGR of 11.03%. North America dominated the market in 2025, with a market share of 8.53%, driven by advanced healthcare infrastructure, robust vaccination programs, and strong public awareness about rotavirus infections. Rotavirus, a highly contagious virus affecting the gastrointestinal tract, is a leading cause of severe diarrhea and vomiting in infants. Vaccination, usually administered orally as part of routine immunization schedules, is the most effective preventive measure.

Market Dynamics

Drivers: A major factor driving market growth is the increasing adoption of national immunization programs, particularly in Southeast Asia, Europe, and North America. Countries like the U.S., Germany, and France have integrated rotavirus vaccines into routine childhood immunizations. For instance, in India, the National Technical Advisory Group on Immunization (NTAGI) recommended including the rotavirus vaccine in the Universal Immunization Programme (UIP) in 2019. Additionally, rising awareness of rotavirus infections and supportive initiatives by international organizations, such as UNICEF and Gavi, are further bolstering market growth.

Restraints: Supply chain challenges pose a constraint on market expansion. Rotavirus vaccines require strict cold-chain storage and transport, and disruptions can lead to temporary shortages or the use of alternative vaccines. UNICEF reported in 2024 that several countries had to switch to alternative products due to supply disruptions from GSK in 2022-2023, which impacted adoption rates.

Opportunities: Expanding vaccination coverage offers growth opportunities, particularly in developing countries such as India and China. Increased government initiatives and inclusion of rotavirus vaccines in national immunization schedules are expected to raise vaccine uptake and market growth. In 2024, Chad introduced vaccines for rotavirus, malaria, and pneumococcal infections under the Expanded Programme on Immunization, reflecting a global trend toward broader preventive coverage.

Challenges: Vaccine safety concerns, such as intussusception (a rare bowel obstruction), may influence public perception and hinder market growth. According to CDC data in 2024, studies indicate a slight increase in intussusception risk post-vaccination, emphasizing the need for effective communication on vaccine safety.

Market Trends

Innovation in vaccine delivery, such as dissolvable patches and novel parenteral formulations, is a prominent trend. Oral vaccines, while convenient, have low bioavailability due to enzymatic degradation and first-pass metabolism. In 2025, Emory University and Micron Biomedical initiated the first clinical trial of CC24, a rotavirus vaccine delivered via dissolvable microarray technology. Such developments highlight the ongoing shift toward more effective and patient-friendly vaccine delivery methods.

Segmentation Analysis

By Type: The live attenuated vaccine segment dominates due to strong, long-lasting immune responses. FDA-approved vaccines like ROTARIX and RotaTeq exemplify the market's reliance on live attenuated formulations. Subunit vaccines, such as the trivalent P2-VP8 candidate by SK Chemicals, are under development and expected to drive future growth.

By Product: RotaTeq holds the leading share, protecting against five rotavirus strains and included in national immunization programs, reducing hospitalization and mortality. ROTARIX remains significant due to its high potency and approval across major regions, including North America, Europe, and Asia Pacific.

By Distribution Channel: Government suppliers dominate, particularly through programs like India's UIP, ensuring free vaccine access and expanding coverage. Hospitals and retail pharmacies contribute significantly due to increasing rotavirus cases and high patient flow.

Regional Outlook

North America: Market valued at USD 2.03 billion in 2025, projected to reach USD 2.19 billion in 2026, led by advanced healthcare infrastructure, high vaccination rates, and R&D capabilities.

Europe: Holds a substantial share, supported by ROTARIX and RotaTeq approvals since 2006, reducing hospitalization rates from rotavirus gastroenteritis (75,000-150,000 annually).

Asia Pacific: Fastest-growing region due to large pediatric populations, government initiatives, and rising awareness. Rotavirus accounts for 40.8% of diarrheal diseases in Southeast Asian children.

Latin America & Middle East & Africa: Expected to grow steadily due to government initiatives and support from organizations like Gavi and UNICEF, which provide vaccines at low cost to improve coverage.

Competitive Landscape

The market is concentrated, with key players including GSK plc., Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Sanofi, Bharat Biotech, and SINOVAC. Companies focus on product innovation, distribution partnerships, and R&D investments. For example, GSK received FDA approval in 2022 for a new liquid ROTARIX vaccine, and Merck expanded RotaTeq supply to China in 2018, demonstrating strategic market positioning.

Conclusion

The global rotavirus vaccines market is poised for significant growth, from USD 5.22 billion in 2025 to USD 5.57 billion in 2026, and reaching USD 12.86 billion by 2034 at a CAGR of 11.03%. Growth is driven by national immunization programs, increasing pediatric populations, innovative vaccine formulations, and government initiatives supporting equitable vaccine access. North America remains a dominant region, while Asia Pacific emerges as the fastest-growing market. Despite challenges like supply chain disruptions and safety concerns, robust R&D and expansion of vaccination coverage are expected to sustain market momentum over the forecast period.

Segmentation By Type

• Live Attenuated
• Others

By Product

• ROTARIX
• RotaTeq
• ROTASIIL
• ROTOVAC
• Others

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Geography

• North America (By Type, Product, Distribution Channel, and Country/Sub-region)
  • U.S.
  • Canada
• Europe (By Type, Product, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Product, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • South Korea
  • Rest of Asia Pacific
• Latin America (By Type, Product, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Product, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Incidence/Prevalence of Rotavirus Infection, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Recommendations/Guidelines for Rotavirus Vaccines
• 4.5. Overview: Vaccination Schedule for Rotavirus
• 4.6. Technological Advancements in the Rotavirus Vaccines
• 4.7. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Live Attenuated
  • 5.1.2. Others
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. ROTARIX
  • 5.2.2. RotaTeq
  • 5.2.3. ROTASIIL
  • 5.2.4. ROTOVAC
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital & Retail Pharmacies
  • 5.3.2. Government Suppliers
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Live Attenuated
  • 6.1.2. Others
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. ROTARIX
  • 6.2.2. RotaTeq
  • 6.2.3. ROTASIIL
  • 6.2.4. ROTOVAC
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital & Retail Pharmacies
  • 6.3.2. Government Suppliers
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Live Attenuated
  • 7.1.2. Others
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. ROTARIX
  • 7.2.2. RotaTeq
  • 7.2.3. ROTASIIL
  • 7.2.4. ROTOVAC
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital & Retail Pharmacies
  • 7.3.2. Government Suppliers
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Live Attenuated
  • 8.1.2. Others
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. ROTARIX
  • 8.2.2. RotaTeq
  • 8.2.3. ROTASIIL
  • 8.2.4. ROTOVAC
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital & Retail Pharmacies
  • 8.3.2. Government Suppliers
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Live Attenuated
  • 9.1.2. Others
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. ROTARIX
  • 9.2.2. RotaTeq
  • 9.2.3. ROTASIIL
  • 9.2.4. ROTOVAC
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital & Retail Pharmacies
  • 9.3.2. Government Suppliers
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Live Attenuated
  • 10.1.2. Others
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. ROTARIX
  • 10.2.2. RotaTeq
  • 10.2.3. ROTASIIL
  • 10.2.4. ROTOVAC
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital & Retail Pharmacies
  • 10.3.2. Government Suppliers
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
    • 11.2.1.1. Overview
    • 11.2.1.2. Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Merck & Co. Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Serum Institute of India Pvt. Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Sanofi
    • 11.2.4.1. Overview
    • 11.2.4.2. Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Bharat Biotech
    • 11.2.5.1. Overview
    • 11.2.5.2. Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. SINOVAC
    • 11.2.6.1. Overview
    • 11.2.6.2. Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)